MCB Accepts, published online ahead of print on 2 August 2010
Mol. Cell. Biol. doi:10.1128/MCB.00146-10

Type I Interferon Signaling Pathway Is A Target For Glucocorticoid Inhibition

Jamie R. Flammer[1,2], Jana Dobrovolna[2], Megan A. Kennedy[2], Yurii Chinenov[2], Christopher K. Glass[3], Lionel B. Ivashkiv[1,2] and Inez Rogatsky[1,2]*

[1]*Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, 1300 York Avenue, New York, NY 10021, USA*

[2]*Hospital for Special Surgery Research Division, 535 East 70th Street, New York, NY, 10021, USA*

[3]*Department of Cellular and Molecular Medicine and Howard Hughes Medical Institute, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA*

***corresponding author:**

rogatskyi@hss.edu

Tel: 212-606-1462

Fax: 212-774-2560

Running Title: Glucocorticoid Regulation of Interferon Signaling

Words in Materials and Methods: 865

Words in Intro+Results+Discussion: 4821

ABSTRACT

Type I Interferon (IFN) is essential for host defenses against viruses; however, dysregulated IFN signaling is causally linked to autoimmunity, particularly systemic lupus erythematosus. Autoimmune disease treatments rely on glucocorticoids (GCs), which act via the GC receptor (GR) to repress proinflammatory cytokine gene transcription. Conversely, cytokine signaling through cognate Jak/STAT pathways is reportedly unaffected or even stimulated by GR. Unexpectedly, we found that GR dramatically inhibited IFN-stimulated gene (ISG) expression in macrophages. The target of inhibition, the heterotrimeric STAT1:STAT2:IRF9 (ISGF3) transcription complex, utilized the GR cofactor GRIP1/TIF2 as a coactivator. Consequently, GRIP1 knockdown, genetic ablation or depletion by GC-activated GR attenuated ISGF3 promoter occupancy, preinitiation complex assembly and ISG expression. Furthermore, this regulatory loop was restricted to cell types such as macrophages expressing GRIP1 protein at extremely low levels, and pharmacological disruption of the GR:GRIP1 interaction or transient introduction of GRIP1 restored RNA polymerase recruitment to target ISGs and the subsequent IFN response. Thus, type I IFN is a cytokine uniquely controlled by GR at the levels of not only production but also signaling, through antagonism with ISGF3 effector function, revealing a novel facet of the immunosuppressive properties of GCs.

INTRODUCTION

Glucocorticoids (GCs) are a class of broadly immunosuppressive steroid molecules that are utilized as combative medicine for numerous inflammatory and autoimmune disorders including asthma, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and many others. The therapeutic effects of GCs are largely attributed to their ability to suppress the production of important cytokines, including tumor necrosis factor (TNF)α (12, 18) and Type I interferon (IFN) (19, 48, 52), which are proposed to be the primary mediators of RA and SLE pathogenesis, respectively. In the case of SLE, for example, the peripheral blood mononuclear cells (PBMCs) display a massive overexpression of conventional Type I IFN target genes ("IFN signature") which appears to correlate with disease activity and severity more than any other marker and is eradicated by administration of GCs (5-7, 29, 60).

GCs convey their actions by diffusing through the cell membrane and binding their cognate GC receptor (GR), a member of the nuclear receptor (NR) superfamily, which at steady state is maintained in a permissive conformation by molecular chaperones such as hsp70 and hsp90 (47). Ligand binding facilitates the translocation of the cytosolic receptor to the nucleus, where liganded GR associates with specific DNA sequences known as GC response elements (GREs) and regulates transcription of target genes. In some cases, GR binds directly, usually as a homodimer, to specific palindromic DNA sequences ("simple" GREs). Conversely, at "tethering" GREs, GR does not itself bind DNA but is instead recruited by other DNA-bound transcription factors such as nuclear factor (NF)-κB and activator protein (AP)1 (35). In contrast to simple GREs, which are commonly associated with transcriptional activation, GR occupancy of tethering GREs typically results in repression of target genes. The divergent ability of GR to activate or repress transcription depends upon many variables including cell type, the DNA

sequence to which GR is recruited, and the composition of available cofactors, which transduce signaling information from the activated GR to basal transcription machinery and chromatin. Of the latter, three members of the p160 family (SRC-1, GRIP1/TIF2/NCOA2/SRC-2 and RAC3/p/CIP/ACTR/AIBI/TRAM-1/SRC-3) are of critical importance in NR transcriptional regulation (59). Interestingly, while all three members of the p160 family are able to mediate transcriptional activation, GRIP1 alone has been implicated in corepression: with GR at tethering GREs (17, 50, 51), with estrogen receptor α at a tethering TNFα-RE (4), and with the myogenic regulatory factor MyoD (57).

Type I IFNs are produced by macrophages (MΦ) and other myeloid cells as an integral component of the host response to viral infection (27), and their production is suppressed by GCs (23, 45). Viral components bind Toll-like receptors (TLRs) to initiate a signaling cascade culminating in the activation of NF-κB and Interferon Regulatory Factor (IRF)3, which then work in concert to induce the transcription and subsequent secretion of Type I IFNs, specifically IFNβ and IFNα4 (38). These IFN subsets initiate an amplification loop by binding the IFNα/β receptor, which induces activation of the constitutively associated tyrosine kinases Tyk2 and Jak1 and the subsequent recruitment and phosphorylation of STAT1 and STAT2 (37). A third transcription factor, IRF9, associates with the STAT1/2 heterodimer through interactions with STAT2, and the resultant trimeric complex, ISGF3, then binds to its cognate IFN-stimulated response elements (ISREs) on the DNA and activates transcription of the Type I IFN-stimulated genes (ISGs). Treatment of MΦ with a synthetic GC, Dexamethasone (Dex), antagonizes the activity of the NF-κB and IRF3 complexes induced by TLRs (46, 49); thus, it is possible that GC-mediated inhibition of ISG expression and eradication of the IFN signature is in part secondary to the suppression of Type I IFN gene transcription. Interestingly, while a wealth of

evidence points to GC-mediated inhibition of cytokine production, much less is known about the effects of GR on the signal transduction pathways initiated by cytokines at the cell surface. It has been shown that GR synergizes with prolactin-activated STAT5 and with IL6-activated STAT3 (34, 36, 54) however, the mechanisms of synergy are unclear. Unexpectedly, we found that ISG expression in murine MΦ induced by exogenously provided Type I IFN was strongly attenuated by co-treatment with Dex, suggesting that the IFN signaling pathway itself is under GC control. Here, we assessed the effects of GCs on Type I IFN-Jak/STAT signaling and dissected the transcriptional regulatory mechanism responsible for the GC sensitivity of the IFN-dependent gene expression. Our findings reveal previously unexplored functional interactions between the GR and IFN pathways, which may underlie the immunosuppressive properties of GCs.

MATERIALS AND METHODS

Plasmids. IP10 promoter-luciferase constructs (-533-Luc, -533-Luc.mt (ISREmt) and p31x2-Luc (2xISRE)), βactin-LacZ, pET-GRIP1 3-RD, pCDNA3-GRIP1 and pCDNA3-GRIP1 N1007 were previously described (49-51). pGEX.IRF9 was generated by excising IRF9 from pCDNA3 with BamHI/NotI and subcloning it into the BamHI/NotI sites of pGEX4T-1 (Amersham-Pharmacia). pGEX.IRF9.N145 was generated from pGEX.IRF9 by incorporating an internal NotI site by site-directed mutagenesis (QuickChange, Stratagene) using mutagenic primers F:5'-CAGCACAGTTCTGCGGCCGCTGAGAGGAAGGAGG-3' and R: 5'-CCTCCTTCCTCTCAGCGGCCGCAGAACTGTGCTG-3'. The C-terminal IRF9 fragment was excised by digestion with NotI and the plasmid was re-ligated. pGEX.IRF9.127C was generated from pGEX.IRF9 by incorporating an internal BamHI site by site-directed mutagenesis using mutagenic primers

F: 5'-CGTCTCTGGCCAGCCAGGGATCCAGAAAGTACCATCAAAGC-3' and
R: 5'-GCTTTGATGGTACTTTCTGGATCCCTGGCTGGCCAGAGACG-3'. The N-terminal IRF9 fragment was excised by digestion with BamHI and the plasmid was re-ligated.
pGEX.IRF9.213C was generated from pGEX.IRF9 by incorporating an internal XbaI site by site-directed mutagenesis using mutagenic primers
F: 5'-CTGGAGTTTCTGCTTCCTCTAGAGCCAGACTACTCACTG-3' and
R: 5'-CAGTGAGTAGTCTGGCTCTAGAGGAAGCAGAAACTCCAG-3'. The N-terminal IRF9 fragment was excised by digestion with XbaI and the plasmid was re-ligated.
pGEX.IRF9.127-208 was generated from pGEX.IRF9.127C by incorporating an internal XhoI site by site-directed mutagenesis using mutagenic primers
F: 5'-GGAATTCCCGGGTCGACTGAGTTTCTGCTTCC-3'
R: 5'-GGAAGCAGAAACTCAGTCGACCCGGGAATTCC-3'. The IRF9 fragment was excised by digestion with BamHI/XhoI and subcloned into the BamHI/XhoI sites of pGEX4T-1.
To generate -533-Luc-κB1, -533-Luc-κB2, and -533-Luc-AP1, the κB1, κB2 or AP1 sites were disrupted by site-directed mutagenesis with the primers
κB1-F: 5'-GCCCTCGGTTTACGGGAAGCTTCCCTCGGGTTGCG-3' and
κB1-R: 5'-CGCAACCCGAGGGAAGCTTCCCGTAAACCGAGGGC-3';
κB2-F: 5'-GGAGCACAAGAGGGGAGAGCCGAATTCCAAGTTCATGGG-3' and
κB2-R: 5'-CCCATGAACTTGGAATTCGGCTCTCCCCTCTTGTGCTCC-3'; and
AP1-F: F:5'-GGTTGCGGAGCCTTGCGCAGTCACCTCCAAAGTC-3' and
AP1-R: 5'-GACTTTGGAGGTGACTGCGCAAGGCTCCGCAACC-3', respectively.

Cell culture and transfections. CV-1 green monkey kidney fibroblasts and murine RAW267.4 MΦ-like cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Mouse 3T3 fibroblasts were cultured in DMEM-10% FBS, supplemented with MEM non-essential amino acids and 1.75 μM 2-mercaptoetanol. BMMΦ were prepared from 8-wk old C57BL/6 mice as in (49) except L929 cell conditioned medium (LCCM) was used for the 6-day MΦ expansion; cells were then scraped and re-seeded into DMEM + 20% FBS for 24 h prior to treatment.

For siRNA, 1.8 x 10^7 RAW267.4 cells were transfected with 200 μmol Control or GRIP1 siRNA (Qiagen) using the Cell Line Nucleofector Kit V (Amaxa VCA-1003) as per the manufacturer's instructions. Cells were allowed to recover for 18 h before treatment.

RAW264.7 cells were transfected in 6-well plates (5 x 10^5 cells/well) using GenePORTER 3000 system (Genlantis) using 275 μl GP3K-Diluent and 28 μl GP3K-Reagent per well in FBS-free DMEM, as per the manufacturer's instructions, and re-fed with DMEM-10% FBS 5 h post-transfection. Cells were allowed to recover for 24 h before treatment.

CV-1 cells were transfected in 24-well plates in FBS-free media using 1 μL lipofectamine and 2 μL PLUS (Invitrogen) per well and re-fed with DMEM + 10% FBS 3 h later. The following day, cells were treated (see Fig. Legends) and harvested for luciferase and β-galactosidase assays 6 h later (51).

Protein purification and in vitro binding assays. GST- and HIS-tagged proteins were generated in *E. coli*. as described (49), except the expression was induced with 0.2 mM IPTG for 5 h at 25˚C. GRIP1 derivatives and GR were produced using the coupled *in vitro*

transcription/translation system (Promega) in the presence of ^{35}S-methionine and (for GR) 1 μM Dex, and binding assays performed in the presence of 0.05% NP-40, as described (49).

Western blotting. For immunoprecipitations, 3T3 fibroblasts or RAW264.7 cells were cultured in 150-mm dishes, treated as indicated in Fig. Legends, and protein extracts were prepared as in (49). 20% of each clarified extract was boiled in 2x SDS sample buffer to generate whole cell extracts (WCE), while the rest was incubated with 4 μg of anti-GRIP1 C-terminal antibody (Santa Cruz sc-6976) at 4˚C overnight, after which 100 μl of a 50% slurry of protein A/G PLUS agarose were added and incubation continued for 1 h at 4˚C. Immunoprecipitates were collected and immunoblotting was performed as in (49). Blotting antibodies used were STAT1 (Santa Cruz sc-346), STAT2 (Santa Cruz sc-22816), pY701-STAT1 (Cell Signaling 9171), pY689-STAT2 (Millipore 07-224), pS727-STAT1 (Cell Signaling 9177), STAT3 (Santa Cruz sc-482), ERK (Santa Cruz sc-94), TIF2 (BD Transduction Laboratories 610985), GRIP1 (Abcam 10491), IRF9 (Santa Cruz sc-10793) and GST (Thermo Scientific, 3001). Primary antibodies were detected using HRP-conjugated anti-mouse or anti-rabbit IgG (Promega).

Chromatin immunoprecipitations. ChIP assays with BMMΦ, RAW264.7 cells and 3T3 mouse fibroblasts were performed as described (2). Antibodies used were STAT1, STAT2, Pol2, GRIP1 (Santa Cruz sc-346, sc-22816, sc-899 and sc-6976, respectively), AcH3 (Millipore 06-599), GR N499 (51) or normal IgG (Santa Cruz sc-2027). Primer pairs for target genes are listed in Table S1.

175 **RNA isolation and real-time PCR.** Total RNA was isolated using the RNeasy Mini Kit
176 (Qiagen). Random-primed cDNA synthesis, qPCR and δδCt analysis were performed as
177 described (49), equalizing total RNA input. GAPDH or βActin were used as a normalization
178 control. Primer pairs for target genes are listed in Table S1.
179
180 **Adenovirus-mediated GRIP1 KD.** BMMΦ from GRIP1$^{flox/flox}$ mice were cultured as described
181 above. On Day 6, 1.5 x 10^6 cells were infected with 1:1000 M.O.I. Ad5-CMV-GFP (Ad-GFP) or
182 Ad5-CMV-Cre (Ad-Cre) (Vector Development Labs) in DMEM + 0.5% FBS for 14 h, re-fed
183 with DMEM + 20% FBS and allowed to recover for 30 h prior to treatment.

Results

Type I IFN target gene expression is directly inhibited by Dex. Unlike cytokine gene expression, cytokine signaling is reportedly unaffected and in some cases even potentiated by GR (36, 54, 55). Treatment of murine bone marrow-derived MΦ (BMMΦ) with Type I IFN induced, as expected, the expression of a series of established ISGs (IP10, CXCL9, ISG56, Rantes, CXCL11, ISG15, ISG54, IL6, OASL1 and Mx1). To our surprise, this induction was markedly attenuated by concurrent administration of Dex (Fig. 1A). As expected, the level of induction of different genes depended on the IFN dose and duration of treatment (Supplementary Fig. S1A and S1B). Similarly, downregulation by Dex varied in magnitude and duration, but was nonetheless observed for each ISG analyzed. This suppression of gene induction was specific to Type I IFN targets, as IFNγ-dependent induction of IRF1was Dex- resistant (Supplementary Fig. S1C).

A similar dramatic inhibition by Dex was observed when nascent unprocessed ISG transcripts were analyzed using intronic primers, ruling out the effects on downstream steps such as mRNA processing or stability (Supplementary Fig. S2A). In some hematopoietic cells, GCs indirectly obstruct the activation of STAT proteins through the induction of intermediary genes, such as the suppressor of cytokine signaling (SOCS1), which interferes with the function of STATs (14). Thus, the sensitivity of ISGs to Dex treatment could result from the induction of a putative IFN signaling inhibitor by the activated GR. Additionally, in T cells, GCs were proposed to alter the expression of upstream signaling components, ultimately affecting STAT4/5 activation (10, 24). However, concurrent treatment with cycloheximide under conditions previously shown to block *de novo* protein synthesis in macrophages (30, 40), did not relieve Dex-dependent inhibition

(Supplementary Fig. S2B), indicating a direct effect of GR on the pre-existing components of the IFN signaling pathway.

Jak/STAT pathway activation is unaffected by Dex treatment. In principle, GR can modulate a given signal transduction pathway by directly altering the activities of kinases or phosphatases. To determine whether GR affects Jak/STAT pathway activation, we assessed STAT1/2 tyrosine phosphorylation (Y701 and Y690, respectively) in response to IFN *vs*. IFN+Dex. STAT proteins were rapidly phosphorylated in response to IFN in both RAW264.7 cells and primary BMMΦ (Fig. 1B and 1C), and this activation mark was unaffected by Dex for up to 2 h of treatment. Similarly, IFN-dependent phosphorylation of STAT1 S727, proposed to be important for full STAT1 activation (21), was also Dex-resistant (Fig. 1C). Thus, activation of the Jak/STAT pathway by Type I IFN appears to be refractory to GC treatment. In addition, as ISGF3 nuclear localization is controlled by IFN-dependent STAT1/2 phosphorylation (33), we assayed the subcellular distribution of STAT1/2 in BMMΦs. Consistent with the results of immunoblotting, indirect immunofluorescence revealed a similar pattern in both IFN- and IFN+Dex-treated cells (not shown).

IFN induction and Dex inhibition of the ISGF3 function is mediated by ISREs. Many ISGs contain binding elements for and are regulated by multiple transcription factors. Because STAT1/2 activation was unaffected by Dex, we questioned whether stimulation and inhibition of ISG expression is specifically mediated by the ISGF3 binding sites, ISREs. We generated a series of IP10-derived luciferase (Luc) reporter constructs and tested their responses to IFN and Dex in a cell-based reporter assay in IFN-responsive CV-1 cells (Fig. 2A). As expected, IFN

229 treatment induced WT reporter activity, while mutation of the ISRE abrogated IFN-mediated
230 induction (Fig. 2B). Although the basal activity of this ISREmt reporter was also significantly
231 reduced relative to WT, phorbol ester PMA, a strong activator of AP1 and NF-κB, considerably
232 induced Luc activity (data not shown), suggesting that the lack of IFN responsiveness was not
233 due to the global disruption of the reporter. In contrast, constructs with an intact ISRE but
234 mutated AP1 and NF-κB elements, either individually (Fig. 2C) or in combination (3˚mt, Fig.
235 2B), were induced by IFN and inhibited by Dex similar to WT. Furthermore, a simplified
236 reporter containing only a dimerized, IFNβ-derived ISRE controlling Luc expression was
237 strongly activated by IFN, and Dex co-treatment abrogated the response (Fig. 2B). Thus, the
238 ISGF3-binding ISRE element was necessary and sufficient for the IFN induction and GC
239 inhibition of ISG-derived reporters.
240
241 **Dex inhibits IFN-induced ISGF3 transcription complex assembly at ISG promoters in**
242 **MΦ.** The results of the cell-based reporter assays suggested that ligand-activated GR could be
243 targeting transcription complex assembly or function at ISG promoter elements. We therefore
244 examined by chromatin immunoprecipitation (ChIP) whether Dex treatment affects the
245 occupancy of the ISGF3 complex at ISREs of IFN-regulated genes in primary BMMΦ. In
246 response to IFN, STAT1 occupancy of ISREs of model ISGs, including IP10, ISG15, ISG56 and
247 CXCL9, increased dramatically, and co-treatment with Dex attenuated this increase for all genes
248 tested (Fig. 3A). A similar pattern was observed for STAT2 (Supplementary Fig. S3A) although
249 overall ChIP signals for STAT2 were modest (relative to the IgG control), likely due to the
250 quality of STAT2 antisera available. It is also possible that the IFN-inducible recruitment of
251 STAT1 and STAT2 to ISG promoters is non-stoichiometric.

Next, we assessed whether the changes in ISGF3 occupancy at ISREs in BMMΦ correlated with alterations in markers of transcriptional activation, such as acetylation of lysines 9 and 14 of histone H3 at ISG regulatory regions. As shown in Fig. 3B, the basal levels of H3AcK9/14 in BMMΦ were highly variable between the individual ISGs at transcription start sites (TSS). Indeed, basal H3 acetylation at the IP10 promoter was only moderately above background of normal IgGs, whereas H3 at ISG15 and ISG56 promoters was strongly acetylated (45- and 30-fold over background, respectively) in untreated cells. Nonetheless, in all cases, some additional acetylation occurred in conjunction with IFN treatment and was diminished by Dex co-treatment (Fig. 3B). No change in the total level of histone H3 was observed in response to either IFN or IFN+Dex at any of the genes tested (not shown).

The definitive mark of transcription initiation is the assembly of basal transcriptional machinery, including RNA Polymerase II (Pol2), into the preinitiation complex at TSS near target promoters. Our ChIP assays revealed that Pol2 occupancy was robustly induced by IFN at the ISG TSS regions. This increase was largely blocked by Dex (Fig. 3C), indicating that GR activation attenuates transcription initiation of these genes.

GR is known to interfere with transcriptional activation by tethering to other DNA-bound regulators and sterically blocking their transactivation domains or preventing the recruitment or activation of the preinitiation complex (22, 35). However, consistent with previous observations (3), we failed to detect a physical interaction *in vitro* between GR and any components of the ISGF3 (not shown), indicating that a tethering mechanism of inhibition is unlikely to operate at the ISREs. Furthermore, no apparent GR occupancy was observed at ISG promoters in IFN- or IFN+Dex-treated RAW264.7 cells; as expected, GR was recruited to its established target gene, GILZ, in a Dex-dependent manner (Supplementary Fig. S3B).

IRF9 and GRIP1 interact *in vitro*. Because ISGF3 nuclear localization was similar in IFN- and IFN+Dex-treated cells, we reasoned that a reduction in apparent ISGF3 occupancy at ISREs may reflect a shorter residence time of the complex on the DNA, perhaps due to Dex-dependent destabilization or loss of associated cofactors. Indeed, activated GR has been proposed to displace essential coregulators from other transcription factors (31). Studies in our lab have shown that GR antagonized IRF3 activity induced by the TLR3 agonists through depleting the p160 family member GRIP1, which is required for IRF3-dependent ISG transcription (49). Because the IRF Association Domain (IAD) of IRF3, responsible for binding GRIP1, is 21% identical (35% similar) to that of IRF9, we investigated the possibility of a protein:protein interaction between IRF9 and GRIP1. We produced *in vitro* a series of GRIP1 derivatives centered across its IRF3-binding repression domain (RD): the NR-interacting domain (NID, aa585-765), 2-RD (aa648–1007, containing NR boxes 2, 3 and the RD), 3-RD (aa715-1007, containing NR box 3 and the RD) and RD alone (aa765-1007) (Fig. 4A) and tested them for their ability to bind purified recombinant full-length GST-IRF9. We found that all but the NID interacted with GST-IRF9, but not GST control; as in our earlier studies with IRF3 or Suv4-20h1 (16, 49), RD bound IRF9 less well than 3-RD (Fig. 4B). Given secondary structure predictions for isolated RD and the fact that the N-terminal 50 aa upstream of RD (which differentiate it from 3-RD) do not enable NID:IRF9 interaction, our results suggest that RD is the major surface of GRIP1 interacting with IRF9 and that the N-terminal 50 aa extension serves to stabilize the RD conformation.

To identify the IRF9 domain(s) responsible for GRIP1 binding, we generated a series of GST-IRF9 deletion mutants and tested their ability to bind GRIP1 2-RD *in vitro*. These included:

N145 (aa1-145, containing the N-terminal DBD and a portion of the linker region), 127C (aa127-393, containing the linker region and the C-terminal IAD), 213C (aa213-393 containing the IAD only), or 127-208 (containing the linker region with a small segment of the IAD) (Fig. 4C). N145 did not bind 2-RD (Fig. 4D), suggesting that, similar to IRF3, the IRF9 DBD is not sufficient for the GRIP1:IRF9 interaction. Conversely, 127C and 213C, but not 127-208, were both able to bind 2-RD. Hence, the GRIP1-interacting region encompasses the IRF9 IAD (aa213–393) and excludes the N-terminal DNA binding and linker domains.

GR binds GRIP1 via NR box 3 (20) immediately adjacent to the IRF9-binding RD, suggesting that GR binding may sterically hinder the formation of the GRIP1:IRF9 complex. To assess whether the GRIP1:IRF9 interaction was affected by GR, we utilized 3-RD, the minimal GRIP1 construct able to bind both IRF9 and GR. As expected, in the presence of 1 μM Dex, *in vitro* transcribed/translated GR bound recombinant HIS-tagged GRIP1 3-RD immobilized on metal affinity resin (Fig. 4E, lanes 1 and 2). Consistent with observations in Fig. 4D, IRF9 127C but not IRF9 N145 bound GRIP1 (Fig. 4E, top panel lane 4 *vs.* 6); furthermore, the GRIP1 3-RD:IRF9 127C interaction was potently inhibited in the presence of GR (Fig. 4E, top panel, lane 4 *vs.* 3). Thus, agonist-activated GR directly disrupts the GRIP1:IRF9 complex.

GRIP1 functions as an ISGF3 coactivator in MΦ. Transcription initiation is a stepwise process involving the sequential recruitment of multiple coregulators which perform diverse functions including covalent modifications of histones and chromatin, recruitment of basal machinery and Pol2, as well as stabilization of the DNA-bound regulator complex itself by facilitating intermolecular interactions and/or preventing its proteosomal degradation. Given the physical interaction between GRIP1 and IRF9, we speculated that GRIP1 may serve as an ISGF3

coactivator, in which case disruption of the GRIP1:IRF9 interaction could alter ISGF3 transcriptional activity by disabling any of the above mechanisms. To test this hypothesis, we used the GRIP1.N1007 derivative (50), which retains the IRF9-binding RD but lacks the AD1/2 responsible for recruiting the secondary coactivators CBP/p300 and CARM1 (42). When co-transfected into CV-1 cells along with the minimal ISRE-driven Luc reporter, GRIP1.N1007 inhibited IFN-induced reporter activity in a dose-dependent manner (Fig. 5A), presumably by binding to IRF9 and displacing endogenous full-length GRIP1 from the ISGF3 complex. Because a dominant-negative approach may suffer from non-specific effects of overexpression, we investigated whether knockdown of endogenous GRIP1 with siRNA would affect ISG expression in RAW264.7 MΦ-like cells. We found that relative to cells transfected with scrambled siRNA (siC), depletion of GRIP1 protein (siG) potently attenuated IFN induction of all ISGs tested (Fig. 5B).

To determine the role of GRIP1 in primary cells, we utilized an *ex vivo* knockdown approach in BMMΦ derived from mice bearing a floxed GRIP1 allele (graciously provided by Pierre Chambon (25)). GRIP1$^{flox/flox}$ BMMΦ were infected in culture with an adenovirus expressing either Cre recombinase (Ad-Cre) or control GFP (Ad-GFP). Indeed, Ad-Cre infection significantly attenuated GRIP1 expression compared to that in Ad-GFP-infected BMMΦ (Fig. 5C, right). Strikingly, the induction of a panel of Type I IFN target genes was nearly abrogated in GRIP1-depleted MΦ (Fig. 5C, left). Furthermore, ISG expression in primary BMMΦ was considerably more sensitive to the loss of GRIP1 than in RAW264.7 cells, likely due to very low levels of GRIP1 protein present in these cells. Combined, these results establish a critical role for endogenous GRIP1 in MΦ in the transcriptional activation of ISGs via the IFN-Jak/STAT pathway.

Pharmacological antagonism of GR:GRIP1 binding restores IFN-dependent gene expression in MΦ. The p160 family members, including GRIP1, interact with GR in conjunction with ligand binding. Specifically, GR agonists such as Dex induce a conformational change in the receptor ligand binding domain (LBD), promoting the formation of the activation function (AF)2 surface, which then recruits GRIP1. In contrast to full agonists, the partial antagonist RU486 precludes the formation of AF2 and thus, p160 recruitment (11). If inhibition of ISGF3 activity by Dex occurs due to the sequestration of GRIP1 from IRF9 by the agonist-bound GR, then competitive antagonism by excess RU486 will displace Dex from the GR LBD, allowing for GRIP1 release and interaction with IRF9, thereby restoring ISG expression. Fig. 6A demonstrates that, on its own, RU486 treatment of BMMΦ did not affect the IFN induction of any ISG tested, and lifted Dex-imposed inhibition in a dose-dependent manner. Furthermore, we observed a remarkable correlation between the mRNA expression data and the effects of GR ligands on preinitiation complex assembly at ISGs. As assessed by ChIP, IFN-induced Pol2 occupancy of ISG TSS was largely unaffected by RU486, while the Dex-dependent reduction in occupancy was reversed in a dose-dependent manner (Fig. 6B). Taken together, these data suggest a scenario in which Dex-mediated inhibition of IFN-induced gene expression is caused by sequestration of GRIP1 by activated GR from its duties as an ISGF3 coactivator.

Glucocorticoid regulation of IFN signaling is cell-type specific. To examine whether GC-dependent regulation of IFN signaling is a common feature of different cell types we assessed the IFN response in murine 3T3 fibroblasts, which express all components of the GR and IFN pathways endogenously. IFN treatment resulted in a potent time-dependent induction of a panel

of ISGs at 0.5, 1 and 2 h (Fig. 7A and not shown); surprisingly, however, the induction appeared completely Dex-resistant. The lack of Dex response did not reflect a disruption of GC pathway, as GR is well-expressed in mouse fibroblasts (Fig. 7B, middle panel) and, as expected, is able to activate GC-responsive genes GILZ and IGFBP1 (Fig. 7A, right).

Interestingly, the level of GRIP1 protein was strikingly different between the murine cell types examined, with fibroblasts expressing a significantly greater amount of GRIP1 relative to BMMΦ or even RAW264.7 cells (Fig. 7B, top panel). We speculated that perhaps the higher GRIP1 expression in 3T3 cells allows for its utilization by both GR and ISGF3, thereby relieving the inhibitory effect of GR on ISG expression. Furthermore, this elevated expression should enable us to employ ChIP at IFN target genes to visualize GRIP1, which in MΦ was below the level of detection. Indeed, a C-terminal antibody to GRIP1 revealed an IFN-dependent increase in GRIP1 occupancy at ISREs of several target ISGs, which was largely unaffected by Dex (Fig. 7C, left). Similarly (and in stark contrast to our observations in MΦ, Fig. 3B), a robust IFN-induced Pol2 recruitment to TSS of these genes was also refractory to Dex treatment (Fig. 7C, right). Overall, we did not expect a dramatic increase in the apparent GRIP1 occupancy in response to IFN in 3T3 cells, as GRIP1 is constitutively nuclear and IRF9 is largely nuclear even in the absence of IFN treatment; consistently, endogenous GRIP1 co-immunoprecipitated IRF9 from mouse fibroblasts prior to IFN stimulation, and this complex was Dex-resistant (Supplementary Fig. S4). It should be noted that the GRIP1 C-terminal antibody used for coIP and ChIP is far less effective for GRIP1 IP than other commercial antibodies raised to GRIP1 epitopes overlapping the IRF9-interacting RD (not shown); importantly, however, this was the only antibody capable of *co-precipitating* the GRIP1:IRF9 complex and detecting GRIP1 at ISREs by ChIP.

Further corroborating our model, we were able to co-immunoprecipitate the GRIP1:IRF9 complex from RAW264.7 cells with the same antibody and, in contrast to fibroblasts, Dex treatment resulted in the loss of IRF9 from GRIP1 (Fig. 7D), replicating the ISG expression pattern in BMMΦ and RAW264.7 cells (Fig. 1A and S1A-B) as well as ISGF3 and Pol II occupancy data in BMMΦ (Fig. 3). We reasoned that if a limiting quantity of GRIP1 is at least in part responsible for the GC sensitivity of ISGF3-dependent gene transcription in MΦ, then exogenously provided GRIP1 may partially or fully restore ISG induction by IFN. Indeed, transiently introduced GRIP1 rescued IP10 and OASL1 expression in RAW264.7 cells even in the presence of Dex (Fig. 7E). Interestingly, we were unable to generate RAW264.7 sublines stably overexpressing GRIP1 under selectable marker, as cells rapidly lost ectopic GRIP1 expression, perhaps indicating that tight regulation of GRIP1 protein level is central to MΦ physiology.

DISCUSSION

Glucocorticoids are potent inhibitors of inflammatory and immune responses in both laboratory and clinical settings. The molecular mechanisms of their action are complex and involve multiple pathways; thus, a complete picture of inflammatory regulation by GCs remains elusive. For instance, GR directly activates transcription of several genes encoding established anti-inflammatory factors, including IκBα, annexin A1, IL-10 and GILZ (22). GR stimulates expression of the DUSP1 phosphatase, which dephosphorylates and inactivates the MAPK proteins p38 and JNK essential for the induction/expression of numerous mediators of inflammation (1). GCs have also been shown to inhibit activating phosphorylation of TBK1, a kinase required for IRF3 activation in response to TLR3/4 signaling (43). Physical interactions

413 between GR and T cell receptors have recently been identified as a novel mode of GR-mediated
414 immunosuppression in T cells (41). Finally, GR directly represses proinflammatory cytokine
415 gene transcription through tethering to other transcription factors such as NF-κB, AP1, CREB,
416 T-bet, and NFAT (22). Despite their diversity, the above mechanisms all share a common
417 regulatory output: the attenuated expression of a host of cytokines, chemokines and other
418 mediators of inflammation. Here, we demonstrate that the Type I IFN-initiated Jak/STAT
419 signaling pathway itself is directly controlled by GR, revealing a previously unrecognized
420 biological activity of GCs.
421 Though Type I IFN signaling has been studied extensively, many questions remain. For
422 example, the Mediator component DRIP150 associates with ISGF3 and potentiates Type I IFN-
423 induced transcription (32); however, the functional relevance of the Mediator complex as a
424 whole in this context has not been resolved. STAT2 was shown to interact with the histone
425 acetyltransferases CBP/p300 (9), but whether this recruitment results in sufficient chromatin
426 remodeling to facilitate transcription is unclear. Our results suggest that the p160 family member
427 GRIP1 is a direct, previously unrecognized coregulator of the ISGF3 complex required for the
428 optimal expression of at least a subset of ISGs.
429 The p160 proteins, while best known as NR coactivators, are becoming increasingly
430 appreciated as cofactors for multiple signaling pathways. GRIP1, in particular, has been shown
431 to interact with and stimulate the activity of the myocyte enhancer factor-2C (Mef2C) and the
432 IRF3 transcription complex (15, 49). At least *in vitro*, GRIP1 binds several other IRF family
433 members including IRF1, IRF5 and IRF7 ((8, 49) and unpublished observations). SRC-1, another
434 p160, potentiates the transcriptional activity of STAT3, STAT5a, STAT5b and STAT6 through
435 physical interactions between the transactivation domains of STATs and the PAS region of SRC-

1 (26, 39). The broad role of p160 proteins as pleiotropic cofactors involved in such diverse transcriptional pathways raises questions regarding their specificity. Interestingly, although all three family members function as coactivators for NRs in overexpression studies and have been used in such assays interchangeably, a growing body of evidence points to the preferential recruitment by a given receptor of one p160 over another in a more physiological setting (59). Furthermore, despite the high degree of conservation of the PAS domains across the p160 family, GRIP1 and RAC3 did not substitute for SRC-1 in its regulation of STATs (39). Thus, it appears unlikely that SRC-1 or RAC3, which lack the domain equivalent to the IRF9-interacting GRIP1 RD, would be functionally redundant with GRIP1 with respect to ISGF3 coactivation.

If GRIP1 is the only p160 protein mediating the cross-talk between GR and ISGF3, the reciprocal question is what promotes its selective recruitment to one regulator *vs.* another? Clearly, the levels of the GRIP1 protein vary dramatically between different cell types, making certain cells, such as MΦ, uniquely receptive to signals that modulate its activity. Meanwhile, GRIP1-mediated pathways in other cell types, may function relatively independently or lack a specific regulatory loop altogether. It is also likely that GRIP1 is differentially regulated post-translationally, depending on the cell type and the nature of the signal. Indeed, the p160 family member SRC-3 displays a distinct phosphorylation fingerprint following treatment with 17β-estradiol compared to that with TNFα, progesterone, or Dex (58, 61). Conceivably, IFN treatment of MΦ imparts post-translational modifications to GRIP1 that preferentially direct it to the ISGF3 complex, whereas Dex triggers a different modification pattern that would facilitate its binding to GR. Discerning such patterns will open up the possibility of signal manipulation, which should be of great therapeutic interest.

Our functional data illustrate that distinct ISGs are differentially affected by the loss of GRIP1, suggesting that the extent to which ISGF3 complex relies on GRIP1 varies between the genes. This raises a question about the mechanistic role of GRIP1 in the context of IFN-activated genes. Coactivators, including the p160 family, stimulate transcription by recruiting histone-modifying enzymes, chromatin remodeling complexes, and/or basal transcription machinery. Indeed, we show that IFN treatment modestly enhances acetylation of H3K9/14, which is partially blocked by Dex. Conceivably, GRIP1 enhances the recruitment of CBP/p300, its known interacting partner; however, as the basal levels of acetylation vary considerably from gene to gene, this mechanism may be important for only a subset of ISGs. The specific DNA sequence of and around the ISREs likely plays an essential role in determining whether and to what extent GRIP1 participates in regulation of a given ISG; in fact, nucleotide sequences appear to determine, in part, cofactor recruitment to many regulators including the ER (28). Remarkably, a single base pair substitution in a GRE leads to changes in GR structure, activity and the composition of the associated coactivator complexes (44, 53).

In addition to serving as recruiters for secondary cofactors and the basal machinery, coactivators may also signal back to the cognate regulator by sterically stabilizing the regulatory complex itself. Indeed, loss of the cofactor MUC1 destabilizes ER and renders it susceptible to proteasomal degradation (56). Likewise, in the absence of cofactors, the yeast transcription factor Met4 dissociates from its ubiquitin ligase SCF^{Met30} which leads to the proteasomal degradation of Met4 (13). In the case of NRs, p160s stabilize agonist in the ligand-binding pocket, thereby facilitating DNA binding by the receptor complexes. Here, we show that IFN-induced ISGF3 occupancy of its target promoters is dramatically reduced in Dex-treated MΦ, suggesting that perhaps GRIP1 stabilizes the complex in a given conformation, which may have

higher binding affinity or stability depending upon the specific DNA sequence. In this scenario, GRIP1 depletion by siRNA, Ad-Cre or activated GR results in variable degrees of dissociation of the ISGF3 complex, effectively causing variable levels of Dex inhibition for different genes.

Identification of GRIP1 as a coactivator for IRF complexes appears somewhat paradoxical, given its role as a GR corepressor at the AP1 and NF-κB tethering GREs (50, 51). Because many ISGs are regulated by both ISGF3 and NF-κB, it is difficult to predict the transcriptional response to a pathogen that induces both the IFN-Jak/STAT pathway and the TLR pathway. In principle, the coactivator and corepressor functions of GRIP1 could operate concurrently, in which case the outcome may depend on the affinity of GRIP1 for either transcription factor, posttranslational modifications induced by the prevailing signal, or a combination thereof. The molecular switch for these functions is as yet unknown; however, deletion studies have shown that the GRIP1 activation domains (AD1/AD2) are inactive when it is recruited as a corepressor at AP1 tethering GREs (50). Further mutational analysis and dissection of signal-specific posttranslational modifications may help to shed light on the molecular mechanisms of the GRIP1 coactivator/corepressor balance. The *in vivo* relevance of these functions to the equilibrium between the immunostimulatory and immunorepressive pathways requires mouse knock-in models in which GRIP1 will solely maintain one function or the other. Our results here suggest a unique role for GRIP1 as a fulcrum that controls the balance of many immunomodulatory pathways and, as such, understanding and exploiting its regulatory surfaces may provide new avenues of therapy for a multitude of immune-mediated diseases.

ACKNOWLEDGEMENTS

We thank Dr. Pierre Chambon (IGBMC, France) for generously providing GRIP1$^{flox/flox}$ mice.

504 This work was funded by grants from the NIH (R01 AI068820), Lupus Research Institute and
505 the Kirkland Center to I.R.; J.R.F. is supported by a predoctoral fellowship from the Cancer
506 Research Institute; Y.C. was supported by the NIH T32 AR07517.

REFERENCES

1. **Abraham, S. M., T. Lawrence, A. Kleiman, P. Warden, M. Medghalchi, J. Tuckermann, J. Saklatvala, and A. R. Clark.** 2006. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med **203:**1883-9.

2. **Adelman, K., M. A. Kennedy, S. Nechaev, D. A. Gilchrist, G. W. Muse, Y. Chinenov, and I. Rogatsky.** 2009. Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling. Proc Natl Acad Sci U S A **106:**18207-12.

3. **Aittomaki, S., M. Pesu, B. Groner, O. A. Janne, J. J. Palvimo, and O. Silvennoinen.** 2000. Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol **164:**5689-97.

4. **An, J., R. C. Ribeiro, P. Webb, J. A. Gustafsson, P. J. Kushner, J. D. Baxter, and D. C. Leitman.** 1999. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci U S A **96:**15161-6.

5. **Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, P. K. Gregersen, and T. W. Behrens.** 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A **100:**2610-5.

6. **Bengtsson, A. A., G. Sturfelt, L. Truedsson, J. Blomberg, G. Alm, H. Vallin, and L. Ronnblom.** 2000. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus **9:**664-71.

7. **Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual.** 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med **197:**711-23.

8. **Bhandare, R., G. Damera, A. Banerjee, J. R. Flammer, S. Keslacy, I. Rogatsky, R. A. Panettieri, Y. Amrani, and O. Tliba.** Glucocorticoid receptor interacting protein-1 restores glucocorticoid responsiveness in steroid-resistant airway structural cells. Am J Respir Cell Mol Biol **42:**9-15.

9. **Bhattacharya, S., R. Eckner, S. Grossman, E. Oldread, Z. Arany, A. D'Andrea, and D. M. Livingston.** 1996. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature **383:**344-7.

10. **Bianchi, M., C. Meng, and L. B. Ivashkiv.** 2000. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci U S A **97:**9573-8.

11. **Bledsoe, R. K., V. G. Montana, T. B. Stanley, C. J. Delves, C. J. Apolito, D. D. McKee, T. G. Consler, D. J. Parks, E. L. Stewart, T. M. Willson, M. H. Lambert, J. T. Moore, K. H. Pearce, and H. E. Xu.** 2002. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell **110:**93-105.

12. **Butler, D. M., A. M. Malfait, L. J. Mason, P. J. Warden, G. Kollias, R. N. Maini, M. Feldmann, and F. M. Brennan.** 1997. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol **159:**2867-76.

13. **Chandrasekaran, S., A. E. Deffenbaugh, D. A. Ford, E. Bailly, N. Mathias, and D. Skowyra.** 2006. Destabilization of binding to cofactors and SCFMet30 is the rate-limiting regulatory step in degradation of polyubiquitinated Met4. Mol Cell **24:**689-99.

14. **Chauhan, S., C. H. Leach, S. Kunz, J. W. Bloom, and R. L. Miesfeld.** 2003. Glucocorticoid regulation of human eosinophil gene expression. J Steroid Biochem Mol Biol **84:**441-52.

15. **Chen, S. L., K. A. Loffler, D. Chen, M. R. Stallcup, and G. E. Muscat.** 2002. The coactivator-associated arginine methyltransferase is necessary for muscle differentiation: CARM1 coactivates myocyte enhancer factor-2. J Biol Chem **277:**4324-33.

16. **Chinenov, Y., M. A. Sacta, A. R. Cruz, and I. Rogatsky.** 2008. GRIP1-associated SET-domain methyltransferase in glucocorticoid receptor target gene expression. Proc Natl Acad Sci U S A **105:**20185-90.

17. **Cho, I. J., and S. G. Kim.** 2009. A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR. Mol Endocrinol **23:**86-99.

18. **Chu, C. Q., M. Field, M. Feldmann, and R. N. Maini.** 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum **34:**1125-32.

19. **Crow, M. K., and J. Wohlgemuth.** 2003. Microarray analysis of gene expression in lupus. Arthritis Res Ther **5:**279-87.

20. **Darimont, B. D., R. L. Wagner, J. W. Apriletti, M. R. Stallcup, P. J. Kushner, J. D. Baxter, R. J. Fletterick, and K. R. Yamamoto.** 1998. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev **12:**3343-56.

21. **Darnell, J. E., Jr.** 1997. STATs and gene regulation. Science **277:**1630-5.

22. **De Bosscher, K., and G. Haegeman.** 2008. MINIREVIEW: Latest perspectives on anti-inflammatory actions of glucocorticoids. Mol Endocrinol.

23. **Dupont, E., K. Huygen, L. Schandene, M. Vandercruys, K. Palfliet, and J. Wybran.** 1985. Influence of in vivo immunosuppressive drugs on production of lymphokines. Transplantation **39:**143-7.

24. **Franchimont, D., J. Galon, M. Gadina, R. Visconti, Y. Zhou, M. Aringer, D. M. Frucht, G. P. Chrousos, and J. J. O'Shea.** 2000. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol **164:**1768-74.

25. **Gehin, M., M. Mark, C. Dennefeld, A. Dierich, H. Gronemeyer, and P. Chambon.** 2002. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol **22:**5923-37.

26. **Giraud, S., F. Bienvenu, S. Avril, H. Gascan, D. M. Heery, and O. Coqueret.** 2002. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem **277:**8004-11.

27. **Grandvaux, N., B. R. tenOever, M. J. Servant, and J. Hiscott.** 2002. The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis **15:**259-67.

28. **Hall, J. M., D. P. McDonnell, and K. S. Korach.** 2002. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol **16:**469-86.

29. **Hooks, J. J., H. M. Moutsopoulos, S. A. Geis, N. I. Stahl, J. L. Decker, and A. L. Notkins.** 1979. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med **301:**5-8.

30. **Kaiser, F., D. Cook, S. Papoutsopoulou, R. Rajsbaum, X. Wu, H. T. Yang, S. Grant, P. Ricciardi-Castagnoli, P. N. Tsichlis, S. C. Ley, and A. O'Garra.** 2009. TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med **206:**1863-71.

31. **Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld.** 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell **85:**403-14.

32. **Lau, J. F., I. Nusinzon, D. Burakov, L. P. Freedman, and C. M. Horvath.** 2003. Role of metazoan mediator proteins in interferon-responsive transcription. Mol Cell Biol **23:**620-8.

33. **Lau, J. F., J. P. Parisien, and C. M. Horvath.** 2000. Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors. Proc Natl Acad Sci U S A **97:**7278-83.

34. **Lechner, J., T. Welte, J. K. Tomasi, P. Bruno, C. Cairns, J. Gustafsson, and W. Doppler.** 1997. Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of beta-casein gene transcription. J Biol Chem **272:**20954-60.

35. **Lefstin, J. A., and K. R. Yamamoto.** 1998. Allosteric effects of DNA on transcriptional regulators. Nature **392:**885-8.

36. **Lerner, L., M. A. Henriksen, X. Zhang, and J. E. Darnell, Jr.** 2003. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev **17:**2564-77.

37. **Levy, D. E., and J. E. Darnell, Jr.** 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol **3:**651-62.

38. **Levy, D. E., I. Marie, and A. Prakash.** 2003. Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol **15:**52-8.

39. **Litterst, C. M., and E. Pfitzner.** 2001. Transcriptional activation by STAT6 requires the direct interaction with NCoA-1. J Biol Chem **276:**45713-21.

40. **Loniewski, K., Y. Shi, J. Pestka, and N. Parameswaran.** 2008. Toll-like receptors differentially regulate GPCR kinases and arrestins in primary macrophages. Mol Immunol **45:**2312-22.

41. **Lowenberg, M., A. P. Verhaar, G. R. van den Brink, and D. W. Hommes.** 2007. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med **13:**158-63.

42. **Ma, H., H. Hong, S. M. Huang, R. A. Irvine, P. Webb, P. J. Kushner, G. A. Coetzee, and M. R. Stallcup.** 1999. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol **19:**6164-73.

43. **McCoy, C. E., S. Carpenter, E. M. Palsson-McDermott, L. J. Gearing, and L. A. O'Neill.** 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. J Biol Chem **283:**14277-85.

44. **Meijsing, S. H., M. A. Pufall, A. Y. So, D. L. Bates, L. Chen, and K. R. Yamamoto.** 2009. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science **324:**407-10.

45. **Norbiato, G., M. Bevilacqua, T. Vago, and M. Clerici.** 1996. Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab **81:**2601-6.

46. **Ogawa, S., J. Lozach, C. Benner, G. Pascual, R. K. Tangirala, S. Westin, A. Hoffmann, S. Subramaniam, M. David, M. G. Rosenfeld, and C. K. Glass.** 2005.

649 Molecular determinants of crosstalk between nuclear receptors and toll-like receptors.
650 Cell **122:**707-21.

651 47. **Pratt, W. B., Y. Morishima, M. Murphy, and M. Harrell.** 2006. Chaperoning of
652 glucocorticoid receptors. Handb Exp Pharmacol**:**111-38.

653 48. **Preble, O. T., R. J. Black, R. M. Friedman, J. H. Klippel, and J. Vilcek.** 1982.
654 Systemic lupus erythematosus: presence in human serum of an unusual acid-labile
655 leukocyte interferon. Science **216:**429-31.

656 49. **Reily, M. M., C. Pantoja, X. Hu, Y. Chinenov, and I. Rogatsky.** 2006. The
657 GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated
658 immunosuppression. EMBO J **25:**108-17.

659 50. **Rogatsky, I., H. F. Luecke, D. C. Leitman, and K. R. Yamamoto.** 2002. Alternate
660 surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid
661 receptor activation and repression contexts. Proc Natl Acad Sci U S A **99:**16701-6.

662 51. **Rogatsky, I., K. A. Zarember, and K. R. Yamamoto.** 2001. Factor recruitment and
663 TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates
664 regulation by phorbol esters and hormones. EMBO J **20:**6071-83.

665 52. **Ronnblom, L., and G. V. Alm.** 2001. A pivotal role for the natural interferon alpha-
666 producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med
667 **194:**F59-63.

668 53. **So, A. Y., C. Chaivorapol, E. C. Bolton, H. Li, and K. R. Yamamoto.** 2007.
669 Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid
670 receptor. PLoS Genet **3:**e94.

671 54. **Stocklin, E., M. Wissler, F. Gouilleux, and B. Groner.** 1996. Functional interactions
672 between Stat5 and the glucocorticoid receptor. Nature **383:**726-8.

673 55. **Takeda, T., H. Kurachi, T. Yamamoto, Y. Nishio, Y. Nakatsuji, K. Morishige, A.**
674 **Miyake, and Y. Murata.** 1998. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT
675 and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response
676 element by IL-6 and glucocorticoid. J Endocrinol **159:**323-30.

677 56. **Wei, X., H. Xu, and D. Kufe.** 2006. MUC1 oncoprotein stabilizes and activates estrogen
678 receptor alpha. Mol Cell **21:**295-305.

679 57. **Wu, H. Y., Y. Hamamori, J. Xu, S. C. Chang, T. Saluna, M. F. Chang, B. W.**
680 **O'Malley, and L. Kedes.** 2005. Nuclear hormone receptor coregulator GRIP1
681 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD.
682 J Biol Chem **280:**3129-37.

58. **Wu, R. C., J. Qin, P. Yi, J. Wong, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley.** 2004. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell **15:**937-49.

59. **Xu, J., and Q. Li.** 2003. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol **17:**1681-92.

60. **Ytterberg, S. R., and T. J. Schnitzer.** 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum **25:**401-6.

61. **Zheng, F. F., R. C. Wu, C. L. Smith, and B. W. O'Malley.** 2005. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol **25:**8273-84.

FIG. LEGENDS

FIG. 1. Dex inhibits IFN-induced gene expression downstream of Jak/STAT pathway activation. (A) Inhibition of IFN-induced gene expression by Dex. BMMΦ were treated for 1 h (ISG56, ISG15, ISG54, OASL1, Mx1), 2 h (IP10, CXCL9, CXCL11, IL6), or 4 h (Rantes) with vehicle (untreated) or 500 U/mL IFN -/+100 nM Dex, as shown. mRNA abundance of ISGF3 target genes was determined by qPCR with GAPDH as normalization control and expressed relative to untreated cells (con=1). Error bars represent ± SEM. Results are representative of at least eight independent experiments. (B,C) Type I IFN-induced phosphorylation of STAT1 and STAT2 is Dex-resistant. RAW 264.7 cells or BMMΦ were cultured for indicated times in the presence of 500 U/mL IFN -/+100 nM Dex, where indicated. STAT1 and STAT2 expression and activation by tyrosine (Y701 and Y690, respectively) or serine (S727, STAT1 only) phosphorylation was assessed by immunoblotting.

FIG. 2. IFN induction and Dex inhibition are mediated by ISREs. (A) Diagram of a series of IP10-derived luciferase reporters, with WT or mutated (stars) promoter elements, and a dimerized, IFNβ-derived ISRE reporter (2xISRE). (B) and (C)10^5 CV-1 cells were transfected with 200 ng pCDNA3.rGR, 35 ng pCMV-LacZ and 200 ng of indicated reporter constructs from (A), and treated the following day for 6 h as indicated. Luciferase activity was normalized to β-galactosidase activity (as a measure of transfection efficiency) and expressed as relative luminescence units (RLU). Error bars represent ± SEM. Results are representative of five independent experiments.

FIG. 3. Dex inhibits IFN-induced transcription complex assembly. BMMΦ were treated as indicated for 30 min. ChIPs were performed using antibodies to STAT1 (A), H3AcK9/K14 (B), Pol2 (C), or isotype-matched control IgG (A-C). Occupancy was determined by qPCR

amplification over ISRE (A) or TSS (B, C) regions of indicated target genes, normalized to internal control (45S) and expressed relative to the mean signal obtained from cells precipitated with control IgG (set to 1). Error bars represent ± SEM. Results are representative of at least three independent experiments.

FIG. 4. GRIP1 and IRF9 interact *in vitro* in a GR-sensitive manner. (A, C) Domain diagrams of full-length GRIP1 (A) and IRF9 (C) and their derivatives produced *in vitro* and recombinantly in *E. coli* as GST-fusion proteins, respectively. (B, D) Mapping the interacting surface on GRIP1 and IRF9. (B) ^{35}S radiolabeled GRIP1 derivatives from (A) were tested for their ability to interact with full length recombinant GST-IRF9 (upper panel) or GST alone (lower panel). (D) Binding assays were performed between ^{35}S-GRIP1 2-RD and GST-IRF9 derivatives from (C). (E) The GRIP1:IRF9 interaction is disrupted by GR. HIS-tagged GRIP1 3-RD immobilized on affinity resin was incubated with GST-IRF9 127C (lanes 3-4) or N145 (lanes 5-6), in the presence or absence of ^{35}S-GR, as indicated. 1 μM Dex was present in all reactions. GR binding to 3-RD was verified by autoradiography (middle) and IRF9 binding was assessed by immunoblotting with GST-specific antibodies (top). Immobilized 3-RD was visualized by Coomassie blue staining (bottom).

FIG. 5. IFN-induced gene expression is dependent upon the presence of active GRIP1. (A) GRIP1.N1007 overexpression attenuates IFN-induced transcription.10^5 CV-1 cells were transiently transfected with 35 ng pCMV-LacZ, 200 ng 2X-ISRE-Luc, and increasing amounts (0, 50, 100 and 200 ng) of pCDNA GRIP1.N1007, or pCDNA3 to equalize the total amount of transfected DNA. The following day, cells were treated for 6 h with 500 U/mL IFN, as indicated, and whole cell lysates were assayed for luciferase activity (exactly as in Fig. 2) (left) or GRIP1 expression by immunoblotting (right)**.** (B) siRNA depletion of GRIP1 antagonizes IFN-

dependent ISG induction. 2 x 10^6 RAW264.7 cells were transfected with 3 μg of siRNA against GRIP1 (siG) or scrambled RNA (siC) as negative control. 18 h later, cells were treated with 500 U/mL IFN for 6 h, as indicated. GRIP1 protein level was analyzed by immunoblotting, with anti-STAT3 blot to verify equal loading (right), and mRNA expression levels of target genes were analyzed by qPCR, as in Fig. 1 (left). (C) Adenovirus-mediated GRIP1 KD in primary MΦ attenuates the IFN response. Primary BMMΦ were derived from GRIP1$^{flox/flox}$ mice as described in Materials and Methods and infected with adenovirus expressing Cre recombinase (Ad-Cre) or control GFP (Ad-GFP). mRNA levels of indicated genes were analyzed by qPCR, as in Fig. 1. ISGs are expressed as a percentage of IFN induction in Ad-GFP-infected cells (100%). GRIP1 is expressed relative to the mean signal obtained from cells infected with control Ad-GFP (set to 1). Error bars represent ± SEM. Results are representative of at least four independent experiments.

FIG. 6. RU486 relieves Dex-mediated inhibition of ISG transcription. (A) BMMΦ were treated for 2 h with 500 U/mL IFN -/+100 nM Dex, -/+ indicated concentrations of RU486 (RU). mRNA abundance of ISGF3 target genes was determined by qPCR with βActin as normalization control and expressed as a percentage of induction by IFN alone (100%). (B) BMMΦ were treated as indicated for 30 min. ChIPs were performed using Pol2 antibodies or isotype-matched control normal IgG (not shown). Occupancy was determined by qPCR amplification over TSS regions of indicated target genes as in Fig. 3. Error bars represent ± SEM.

FIG. 7. The effect of glucocorticoids on ISG expression depends on the GRIP1 protein level in a cell. (A) ISG expression in 3T3 mouse fibroblasts is Dex-resistant. 3T3 cells were treated for indicated times with 500 U/mL IFN -/+ 100 nM Dex (left) or Dex alone (right), as shown, and mRNA abundance of indicated genes was determined by qPCR with βActin as normalization control. (B) GRIP1 protein level varies dramatically between cell types. An

equivalent amount of whole cell extracts (WCE) from BMMΦ, RAW264.7 cells or 3T3 fibroblasts were fractionated by SDS-PAGE and the expression of GRIP1, GR and ERK1/2 (as a loading control) was assessed by immunoblotting. (C) IFN-dependent GRIP1 and Pol2 recruitment to ISGs in fibroblasts is Dex-resistant. 3T3 cells were treated for 1 h, as indicated, and GRIP1 and Pol2 occupancy at the ISRE or TSS, respectively, of indicated genes was determined by qPCR, normalized to internal control (45S) and expressed relative to the mean signal obtained from cells precipitated with control IgG (set to 1). (D) GRIP1:IRF9 interaction in RAW264.7 cells is sensitive to Dex. RAW264.7 cells were treated as shown for 1 h and lysates were prepared. 20% of each lysate was boiled in sample buffer to generate WCE, whereas the rest was precipitated with anti-GRIP1 antibody (αGRIP1 IP). Protein complexes were adsorbed on protein A/G PLUS agarose beads, boiled in sample buffer and separated by SDS-PAGE along with WCE. GRIP1 and IRF9 were detected by immunoblotting. (E) GRIP1 overexpression in RAW264.7 cells rescues ISG expression. 0.5 x 10^6 RAW264.7 cells were transfected with 1-2 μg of pCDNA-GRIP1 (GRIP1) or empty vector (vec) using GenePORTER 3000 (Genlantis) as per the manufacturer's instructions. 24 h later, cells were treated with IFN -/+ Dex, as indicated, for 2 h and mRNA expression levels of IP10 and OASL1 were analyzed by qPCR, as in Fig. 1.